{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:50:06Z","timestamp":1794243006334,"version":"4.9.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dabrafenib and trametinib, approved for the treatment of BRAF-mutant metastatic melanoma, are associated with a spectrum ophthalmic toxicity including pan-uveitis and serous retinopathy. Vogt\u2013Koyanagi\u2013Harada (VKH) is a systemic inflammatory disorder characterized by bilateral granulomatous pan-uveitis, exudative retinal detachments, and often associated with extraocular manifestations such as tinnitus, vitiligo, headaches, or encephalopathy. We present a 49-year-old woman with stage IV metastatic cutaneous melanoma developed bilateral acute pan-uveitis with multifocal serous retinal detachments, 4\u00a0months after starting combined dabrafenib and trametinib therapy. Clinical assessment, together with fluorescein angiography, optical coherence tomography, and serology led to the diagnosis of a (VKH)-like uveitis. Prompt systemic corticosteroids and modification of the dosing schedule of the suspected offending agents resulted in the resolution of intraocular inflammation and serous retinal detachments. This case underscores the importance of the prompt recognition of the association between VKH-like uveitis and BRAF\/MEK inhibitors, enabling early intervention without compromising metastatic melanoma treatment.<\/jats:p>","DOI":"10.1093\/jscr\/rjae104","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T09:14:48Z","timestamp":1709802888000},"source":"Crossref","is-referenced-by-count":6,"title":["VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report"],"prefix":"10.1093","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3798-1572","authenticated-orcid":false,"given":"Cadric","family":"Gunaratnam","sequence":"first","affiliation":[{"name":"University of Queensland School of Medicine, , Brisbane 4006, Australia"},{"name":"Princess Alexandra Hospital Department of Ophthalmology, , Brisbane 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Muzicenco","sequence":"additional","affiliation":[{"name":"School of Medicine , James Cook University, Townsville 4814, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premala","family":"Sivagurunathan","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital Department of Ophthalmology, , Brisbane 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Hogden","family":"Franzco","sequence":"additional","affiliation":[{"name":"University of Queensland School of Medicine, , Brisbane 4006, Australia"},{"name":"Princess Alexandra Hospital Department of Ophthalmology, , Brisbane 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2024030709143557100_ref1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024030709143557100_ref2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-021-00593-9","article-title":"Combining BRAF\/MEK inhibitors with immunotherapy in the treatment of metastatic melanoma","volume":"22","author":"Ziogas","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024030709143557100_ref3","doi-asserted-by":"crossref","first-page":"NP109","DOI":"10.1177\/1120672120962044","article-title":"A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib\/trametinib therapy for advanced melanoma","volume":"32","author":"Brambati","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"2024030709143557100_ref4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/imt-2019-0206","article-title":"Concurrent Vogt\u2013Koyanagi\u2013Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma","volume":"12","author":"Gambichler","year":"2020","journal-title":"Immunotherapy"},{"key":"2024030709143557100_ref5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","article-title":"Ocular safety profile of BRAF and MEK inhibitors","volume":"128","author":"Mettler","year":"2021","journal-title":"Ophthalmology"},{"key":"2024030709143557100_ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2016.1246666","article-title":"Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report","volume":"26","author":"Lim","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"2024030709143557100_ref7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-023-00339-0","article-title":"Ocular side effects of Trametinib and Dabrafenib: a case report","volume":"13","author":"Tar\u0131m","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["Journal of Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2024\/3\/rjae104\/56876617\/rjae104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2024\/3\/rjae104\/56876617\/rjae104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T09:14:54Z","timestamp":1709802894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jscr\/article\/doi\/10.1093\/jscr\/rjae104\/7623227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jscr\/rjae104","relation":{},"ISSN":["2042-8812"],"issn-type":[{"value":"2042-8812","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,3]]},"article-number":"rjae104"}}